Primary: adverse events ‐ any adverse event treatment‐related (application site pruritus) · participants with moderate to severe hand eczema
Corticosteroid creams/ointments: clobetasol propionate foam showed no clear difference in primary: adverse events ‐ any adverse event treatment‐related… compared with vehicle foam (moderate certainty).
1 finding from 1 review
Secondary: reduction in severity, participant‐rated scoring · participants with moderate to severe hand eczema
Corticosteroid creams/ointments: clobetasol propionate foam probably leads to higher secondary: reduction in severity, participant‐rated scoring compared with vehicle foam (moderate certainty).
1 finding from 1 review
Secondary: reduction in severity, investigator‐rated scoring ‐ improvement at least 2 grades · participants with moderate to severe hand eczema
Corticosteroid creams/ointments: clobetasol propionate foam showed no clear difference in secondary: reduction in severity, investigator‐rated scoring ‐… compared with vehicle foam (moderate certainty).
1 finding from 1 review
Primary: investigator‐rated good/excellent control of symptoms · people (all patch‐tested) with hand eczema > 6 months that had cleared upon daily treatment for a maximum of 9 weeks with mometasone…
Corticosteroid creams/ointments: mometasone furoate cream 3 times/week showed no clear difference in primary: investigator‐rated good/excellent control of symptoms compared with 2 times/week (low certainty).
1 finding from 1 review
Primary: participant‐rated good/excellent control of symptoms Not measured · people (all patch‐tested) with hand eczema > 6 months that had cleared upon daily treatment for a maximum of 9 weeks with mometasone…
The review found no eligible studies for this question.
1 finding from 1 review
Primary outcome 3: Adverse events · people (all patch‐tested) with hand eczema > 6 months that had cleared upon daily treatment for a maximum of 9 weeks with mometasone…
Corticosteroid creams/ointments: mometasone furoate cream 3 times/week showed no clear difference in primary: adverse events compared with 2 times/week (low certainty).
1 finding from 1 review
Primary outcome: Global improvement of disease activity or damage assessed by a medical practitioner or by participants · children and adolescents with active morphea (linear scleroderma, generalised morphea and mixed subtype: linear and circumscribed).
Oral methotrexate and oral prednisone may leads to higher primary outcome: Global improvement of disease activity or damage… compared with placebo and oral prednisone (low certainty).
1 finding from 1 review
Adverse events associated with treatment · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…
Narrowband UVB phototherapy may leads to lower primary outcome: Adverse effects compared with medium‐dose UVA‐1 phototherapy (50 J/cm²) (low certainty).
1 finding from 1 review
Secondary outcome: Improvement of disease activity (skin softening) · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…
1 finding from 1 review
Secondary outcome: Improvement of disease damage ‐ not measured · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…
The review found no eligible studies for this question.
1 finding from 1 review
Primary outcome: Global improvement of disease activity or damage assessed by a medical practitioner or by participants · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…
1 finding from 1 review
Adverse events associated with treatment · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…
Narrowband UVB phototherapy may leads to lower primary outcome: Adverse effects compared with low‐dose UVA‐1 phototherapy (20 J/cm²) (low certainty).
1 finding from 1 review
Secondary outcome: Improvement of disease activity (skin softening) · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…
1 finding from 1 review
Secondary outcome: Improvement of disease damage ‐ not measured · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…
The review found no eligible studies for this question.
1 finding from 1 review
Adverse events associated with treatment · children and adolescents with active morphea (linear scleroderma, generalised morphea and mixed subtype: linear and circumscribed).
Oral methotrexate and oral prednisone showed no clear difference in primary outcome: Adverse effects compared with placebo and oral prednisone (low certainty).
1 finding from 1 review
Secondary outcome: Improvement of disease activity (reduction in lesion size) · children and adolescents with active morphea (linear scleroderma, generalised morphea and mixed subtype: linear and circumscribed).
1 finding from 1 review
Secondary outcome: Improvement of disease damage ‐ not measured · children and adolescents with active morphea (linear scleroderma, generalised morphea and mixed subtype: linear and circumscribed).
1 finding from 1 review
Primary outcome: Global improvement of disease activity or damage assessed by a medical practitioner or by participants · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…
1 finding from 1 review
Adverse events associated with treatment · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…
Medium‐dose UVA‐1 phototherapy (50 J/cm²) showed no clear difference in primary outcome: Adverse effects compared with low‐dose UVA‐1 phototherapy (20 J/cm²) (low certainty).
1 finding from 1 review
Secondary outcome: Improvement of disease activity (skin softening) · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…
1 finding from 1 review